Power calculations and placebo effect for future clinical trials in progressive supranuclear palsy

Keyphrases

• Activities of Daily Living 33%
• Change Score 16%
• Clinical Trials 100%
• Davunetide 16%
• Disease Duration 16%
• Disease-modifying Agents 16%
• Disease-modifying Therapy 16%
• Generated Data 16%
• Neuroprotective 16%
• Number of Patients 16%
• Placebo 16%
• Placebo Effect 100%
• Power Calculation 100%
• Progressive Supranuclear Palsy 100%
• Randomized Placebo-controlled Trial 16%
• Rating Scales 50%
• Sample Size Calculation 16%
• Tideglusib 16%

Medicine and Dentistry

• Activities of Daily Living 33%
• Clinical Trial 100%
• Davunetide 16%
• Disease 33%
• Disease Duration 16%
• Neuroprotective Agent 16%
• Placebo 33%
• Placebo Effect 100%
• Progressive Supranuclear Palsy 100%
• Rating Scale 50%
• Tideglusib 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Clinical Trial 100%
• Davunetide 16%
• Disease 33%
• Disease Duration 16%
• Neuroprotective Agent 16%
• Placebo 100%
• Progressive Supranuclear Palsy 100%
• Tideglusib 16%